Company / Free Cash Flow
Gilead Sciences Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$9.5B
FY2025
5-year range
$7.5B / $10.8B
FY2021-FY2025
Trend
-8.2%
vs FY2024
Sector context
#5 of 194
Health Care
What the data says
Among 194 Health Care companies, Gilead Sciences is in the top 3% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $7.5B in FY2022 to $20.5B in FY2017.
Based on SEC 10-K filings.
$9.5B in FY2025 with a 5-year CAGR of +4.7%. Top quartile in the Health Care sector.
Declined from $10.8B to $9.5B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- +4.7%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 194This company $9.5B Sector average $470.6M
▼
+1909.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.7%, indicating consistent growth.
- In FY2025, free cash flow decreased 8.2% year-over-year.
- Ranks #5 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5B | -8.2% |
| FY2024 | $10.3B | -4.6% |
| FY2023 | $10.8B | +43.7% |
| FY2022 | $7.5B | -9.6% |
| FY2021 | $8.3B | +10.7% |
| FY2020 | $7.5B | -33.5% |
| FY2019 | $11.3B | -30.6% |
| FY2018 | $16.3B | -20.5% |
| FY2017 | $20.5B | +67.2% |
| FY2016 | $12.3B | -40.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026